BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

22 Apr 2024 05:45:00 By Nasdaq GlobeNewswire

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

07 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

20 Mar 2024 05:15:00 By Nasdaq GlobeNewswire

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

20 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

11 Mar 2024 06:45:00 By Nasdaq GlobeNewswire

BioNTech Announces Planned Retirement of Sean Marett

07 Mar 2024 05:45:00 By Nasdaq GlobeNewswire

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

06 Mar 2024 05:45:00 By Nasdaq GlobeNewswire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 

08 Feb 2024 04:45:00 By Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

31 Jan 2024 05:45:00 By Nasdaq GlobeNewswire

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

22 Jan 2024 05:45:00 By Nasdaq GlobeNewswire

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

09 Jan 2024 05:45:00 By Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

18 Dec 2023 12:15:00 By Nasdaq GlobeNewswire

BioNTech to Inaugurate First African Site on December 18, 2023

12 Dec 2023 05:45:00 By Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

06 Nov 2023 05:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

26 Oct 2023 05:45:00 By Nasdaq GlobeNewswire

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

23 Oct 2023 10:30:00 By Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

23 Oct 2023 05:45:00 By Nasdaq GlobeNewswire

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

19 Oct 2023 05:45:00 By Nasdaq GlobeNewswire

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

16 Oct 2023 02:30:00 By Nasdaq GlobeNewswire